Seo, Minkoo Kim, Jin-Chul Kim, Hyung-Ki Choi, Eun Wook Jeong, Suyeong Nam, Ki Chang Jang, Mihue 2024-01-19T23:04:48Z 2024-01-19T23:04:48Z 2021-09-03 2018-03 1687-966X https://pubs.kist.re.kr/handle/201004/121642 Multipotent stem cells have the capacity to generate terminally differentiated cell types of each lineage; thus, they have great therapeutic potential for a wide variety of diseases. The most widely available stem cells are derived from human tissues, and their use for therapeutic application is limited by their high cost and low productivity. Herein, we report that conditioned media of mesenchymal stem cells (MSCs) isolated from deer antlers enhanced tissue regeneration through paracrine action via a combination of secreted growth factors and cytokines. Notably, DaMSC-conditioned media (DaMSC-CM) enhanced hair regeneration by activating the Wnt signaling pathway. In addition, DaMSC-CM had regenerative potential in damaged skin tissue through induction of skin regeneration-related genes. Remarkably, we identified round vesicles derived from DaMSC-CM, with an average diameter of similar to 120nm that were associated with hair follicle formation, suggesting that secretory vesicles may act as paracrine mediators for modulation of local cellular responses. In addition, these secretory vesicles could regulate the expression of Wnt-3a, Wnt-10b, and lymphoid enhancer-binding factor-1 (LEF-1), which are related to tissue renewal. Thus, our findings demonstrate that the use of DaMSC-CM as a unique natural model for rapid and complete tissue regeneration has possible application for therapeutic development. English HINDAWI LTD STROMAL CELLS IN-VITRO EXOSOMES PROTEINS RECOVERY THERAPY TRIAL SIZE A Novel Secretory Vesicle from Deer Antlerogenic Mesenchymal Stem Cell-Conditioned Media (DaMSC-CM) Promotes Tissue Regeneration Article 10.1155/2018/3891404 1 STEM CELLS INTERNATIONAL, v.2018 STEM CELLS INTERNATIONAL 2018 scie scopus 000429622600001 2-s2.0-85056114055 Cell & Tissue Engineering Cell Biology Article STROMAL CELLS IN-VITRO EXOSOMES PROTEINS RECOVERY THERAPY TRIAL SIZE